State Street
RNAC icon

State Street’s Cartesian Therapeutics RNAC Stock Holding History

State Street’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.23M Buy
200,337
+1,370
+0.7% +$9.76K ﹤0.01% 3438
2025
Q4 		$1.43M Buy
198,967
+1,301
+0.7% +$10.5K ﹤0.01% 3436
2025
Q3 		$2.02M Buy
197,666
+3,397
+2% +$38.2K ﹤0.01% 3337
2025
Q2 		$2.02M Sell
194,269
-6,856
-3% -$73K ﹤0.01% 3311
2025
Q1 		$2.65M Buy
201,125
+28,505
+17% +$509K ﹤0.01% 3144
2024
Q4 		$3.09M Buy
172,620
+15,125
+10% +$306K ﹤0.01% 3166
2024
Q3 		$2.54M Buy
157,495
+3,830
+2% +$59.8K ﹤0.01% 3246
2024
Q2 		$4.15M Buy
153,665
+84,104
+121% +$2.01M ﹤0.01% 3006
2024
Q1 		$1.36M Sell
69,561
-3,834
-5% -$81.3K ﹤0.01% 3395
2023
Q4 		$1.52M Buy
73,395
+5,620
+8% +$168K ﹤0.01% 3386
2023
Q3 		$2.16M Buy
67,775
+2,268
+3% +$75.8K ﹤0.01% 3296
2023
Q2 		$2.2M Buy
65,507
+51,450
+366% +$1.84M ﹤0.01% 3365
2023
Q1 		$586K Hold
14,057
– – ﹤0.01% 3690
2022
Q4 		$477K Sell
14,057
-83
-0.6% -$3.53K ﹤0.01% 3786
2022
Q3 		$696K Buy
14,140
+1,280
+10% +$70.3K ﹤0.01% 3669
2022
Q2 		$505K Sell
12,860
-46,840
-78% -$1.39M ﹤0.01% 3824
2022
Q1 		$2.2M Buy
59,700
+2,689
+5% +$168K ﹤0.01% 3527
2021
Q4 		$5.58M Sell
57,011
-90,655
-61% -$9.75M ﹤0.01% 3185
2021
Q3 		$18.4M Buy
147,666
+100,580
+214% +$12.1M ﹤0.01% 2533
2021
Q2 		$5.91M Buy
47,086
+7,061
+18% +$841K ﹤0.01% 3173
2021
Q1 		$5.43M Buy
40,025
+2,256
+6% +$280K ﹤0.01% 3016
2020
Q4 		$3.43M Sell
37,769
-1,716
-4% -$149K ﹤0.01% 3143
2020
Q3 		$2.94M Buy
39,485
+2,111
+6% +$162K ﹤0.01% 3045
2020
Q2 		$3.18M Buy
+37,374
New +$3.39M ﹤0.01% 2991
2019
Q4 		– Sell
-709
Closed -$37K – 3824
2019
Q3 		$37K Buy
709
+20
+3% +$1.06K ﹤0.01% 3736
2019
Q2 		$37K Sell
689
-9,968
-94% -$679K ﹤0.01% 3742
2019
Q1 		$758K Buy
10,657
+2,156
+25% +$137K ﹤0.01% 3392
2018
Q4 		$678K Buy
8,501
+4
+0% +$913 ﹤0.01% 3398
2018
Q3 		$3.96M Buy
8,497
+1,225
+17% +$492K ﹤0.01% 2973
2018
Q2 		$2.89M Buy
7,272
+567
+8% +$201K ﹤0.01% 3111
2018
Q1 		$2.05M Sell
6,705
-22
-0.3% -$6.27K ﹤0.01% 3160
2017
Q4 		$1.98M Buy
6,727
+443
+7% +$194K ﹤0.01% 3185
2017
Q3 		$3.44M Buy
6,284
+1,203
+24% +$640K ﹤0.01% 2965
2017
Q2 		$3.03M Buy
5,081
+2,755
+118% +$1.22M ﹤0.01% 2965
2017
Q1 		$997K Buy
2,326
+4
+0.2% +$1.68K ﹤0.01% 3262
2016
Q4 		$1.2M Buy
+2,322
New +$1.36M ﹤0.01% 3246

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

State Street's RNAC Position: Q1 2026 in Review

State Street increased its Cartesian Therapeutics (RNAC) stake by 0.69% in Q1 2026, buying an estimated $9.76K and bringing the position to 200,337 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #3438.

State Street first reported a position in RNAC in Q4 2016 and has held it in 36 quarters since. The position peaked at $18.4M in Q3 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • State Street held 200,337 shares of Cartesian Therapeutics worth $1.23M as of Q1 2026.
  • State Street bought 1,370 Cartesian Therapeutics shares in Q1 2026, an estimated $9.76K.
  • Cartesian Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3438 holding.
  • State Street first reported a position in Cartesian Therapeutics in Q4 2016 and has held it in 36 quarters since.
  • State Street's Cartesian Therapeutics position peaked at $18.4M in Q3 2021.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.